Teva Pharmaceutical Industries Limited / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €15.03B +1.0% N/A N/A N/A N/A
    (estimated) €14.88B +3.6% €3.04B +12.5% 20.4% +0.016 pp €3.05B +33.9% 20.5% +0.046 pp
    (estimated) €14.35B +0.9% €2.70B +7.0% 18.8% +0.011 pp €2.28B +11.9% 15.9% +0.016 pp
    (estimated) €14.22B +0.8% €2.52B -280.5% 17.7% +0.28 pp €2.03B +36.7% 14.3% +0.038 pp
    €14.11B +4.4% -€1.40B +193.2% -9.9% -0.064 pp €1.49B -7.9% 10.5% -0.014 pp
    €13.52B +6.2% -€476.80M -76.2% -3.5% +0.12 pp €1.62B -11.4% 12.0% -0.024 pp
    €12.73B -6.0% -€2.01B -664.3% -15.8% -0.18 pp €1.82B +57.2% 14.3% +0.058 pp
    €13.54B -4.7% €355.68M -110.5% 2.6% +0.27 pp €1.16B -24.2% 8.6% -0.022 pp
    €14.21B -1.4% -€3.40B +299.4% -24.0% -0.18 pp €1.53B +173.1% 10.8% +0.069 pp
    €14.40B -10.4% -€852.10M -53.5% -5.9% +0.055 pp €560.39M -78.8% 3.9% -0.13 pp
    €16.08B -15.8% -€1.83B -86.8% -11.4% +0.61 pp €2.64B -29.3% 16.4% -0.031 pp
    €19.09B +2.2% -€13.87B -5,043.8% -72.7% -0.74 pp €3.74B -28.5% 19.6% -0.084 pp
    €18.68B +11.5% €280.62M -79.3% 1.5% -0.066 pp €5.23B -3.0% 28.0% -0.042 pp
    €16.76B -3.1% €1.35B -48.0% 8.1% -0.070 pp €5.39B +4.3% 32.1% +0.023 pp
    €17.29B -0.2% €2.61B +140.7% 15.1% +0.088 pp €5.17B +41.9% 29.9% +0.089 pp
    €17.33B -0.0% €1.08B -35.4% 6.2% -0.034 pp €3.64B -24.8% 21.0% -0.069 pp
    €17.33B +10.9% €1.67B -28.9% 9.7% -0.054 pp €4.84B +9.4% 27.9% -0.0039 pp
    €15.62B +13.6% €2.35B -17.2% 15.1% -0.056 pp €4.42B +7.0% 28.3% -0.017 pp
    €13.75B +16.0% €2.84B +66.6% 20.7% +0.063 pp €4.13B +18.4% 30.1% +0.0062 pp
    €11.86B +25.4% €1.71B +215.0% 14.4% +0.087 pp €3.49B +4.6% 29.4% -0.058 pp
    €9.45B +17.8% €541.62M -67.5% 5.7% -0.15 pp €3.34B +66.1% 35.3% +0.10 pp
    €8.02B +11.9% €1.66B +257.5% 20.7% +0.14 pp €2.01B -3.8% 25.0% -0.041 pp
    €7.17B +60.1% €465.71M -49.1% 6.5% -0.14 pp €2.09B +45.7% 29.1% -0.029 pp
    €4.48B +9.4% €914.62M +223.2% 20.4% +0.14 pp €1.43B +7.7% 32.0% -0.0050 pp
    €4.09B +46.5% €283.01M -52.0% 6.9% -0.14 pp €1.33B +87.0% 32.5% +0.070 pp
    €2.79B +30.1% €589.39M +68.4% 21.1% +0.048 pp €711.45M +62.2% 25.5% +0.050 pp
    €2.15B +21.2% €349.97M +47.5% 16.3% +0.029 pp €438.50M +26.2% 20.4% +0.0081 pp
    €1.77B +18.7% €237.30M +87.5% 13.4% +0.049 pp €347.33M +59.7% 19.6% +0.050 pp
    €1.49B +36.5% €126.59M +26.0% 8.5% -0.0071 pp €217.54M +15.6% 14.6% -0.026 pp
    €1.09B +14.9% €100.51M +71.3% 9.2% +0.030 pp €188.23M +7.2% 17.2% -0.012 pp
    €951.81M -0.1% €58.68M -32.2% 6.2% -0.029 pp €175.54M -19.9% 18.4% -0.046 pp
    €952.66M +17.1% €86.57M +38.3% 9.1% +0.014 pp €219.21M +100.0% 23.0% +0.095 pp
    €813.54M +42.8% €62.61M -8.0% 7.7% -0.043 pp €109.60M -41.1% 13.5% -0.19 pp
    €569.52M +13.6% €68.07M +11.5% 12.0% -0.0023 pp €185.94M +85.2% 32.6% +0.13 pp
    €501.28M +17.1% €61.07M +24.5% 12.2% +0.0073 pp €100.39M +41.8% 20.0% +0.035 pp
    €428.18M +23.4% €49.04M +76.4% 11.5% +0.034 pp €70.79M +49.5% 16.5% +0.029 pp
    €346.90M +24.3% €27.81M +37.6% 8.0% +0.0077 pp €47.34M +76.8% 13.6% +0.040 pp
    €279.00M €20.21M 7.2% €26.78M 9.6%

    Notifications